BRUSSELS, BELGIUM--(MARKET WIRE)--Jul 26, 2007 -- Revenue increased to 1.86 billion euro driven by strong performance of Keppra® and Xyzal® Underlying profitability (recurring EBITDA) increased by 14%* to 485 million euro Synergy target increased from 300 million euro to 380 million euro
